Christian Carlsen, Business Director of NNE, showcases the diverse Danish ecosystem and explains how NNE is striving to accomplish its mission of adding value to the medical cannabis industry.

Denmark proudly supports its healthcare services, showcasing a long history of life science, further coupled with valuable experience in agriculture and horticulture. Now, with a rapidly evolving medical cannabis industry, Denmark has the opportunity to cohesively align its progressing ecosystem to work together with diverse companies emerging in the medical cannabis marketplace. NNE, the international company specialising in pharma engineering, is at the forefront of this movement.

Along with Invest in Denmark and Invest in Odense, Danish pharma specialist NNE is launching the first public-private partnership in Denmark.

A strong horticultural heritage, a strong pharma sector, combined with progressive and clear legislation for production of medical cannabis made Denmark a first mover in Europe.

Now, the first medical cannabis investor summit in Denmark is already attracting attention, reinforced by political support for an extension of the trial program aired by Minister of Health.

Nine months ago, the Danish pharma specialist NNE sowed a seed – a team providing strategic business consulting on growing, producing and distributing medical cannabis.

Cannabis cultivator Atlas Biotechnologies is the latest Canadian firm to establish a base in Denmark where a medical cannabis trial is thriving.

Atlas follows in the footsteps of Canada-based international producers Aphria, ICC International Cannabis, Aurora Cannabis, Canopy Growth and The Green Organic Dutchman. Atlas Growers Denmark has leased a 170,000 sq. ft. indoor mushroom farm for conversion into cannabis production facility.

Marijuana and sperm have a complicated and confusing relationship. Some studies have found that men who smoke marijuana have a higher sperm count. Other research has found they have a lower sperm count. Regardless, what’s decided is that the hundreds of chemicals in marijuana tinker with sperm on a deep level — and new research demonstrates why.

The future looks bright for the Danish medical cannabis industry, but speaking to Rikke Jakobsen, CEO of Cannabis Denmark, there is still work to be done.

The Danish medical cannabis industry is a dynamically evolving world, with this in mind, Health Europa spoke with Rikke Jakobsen, CEO of Cannabis Denmark in late 2018 to discuss the pioneering medical cannabis pilot and development programmes the country had recently launched, along with the impact this was set to have on patients, growers and healthcare professionals.

With the Danish medical cannabis pilot scheme now well underway, then Minister for Health Ellen Trane Nørby, talks her vision for the programme.

Ellen Trane Nørby in her capacity as Minister of Health oversaw the implementation of the landmark medical cannabis pilot scheme in Denmark. Addressing attendees at the MJBiz Daily European Cannabis Symposium in Copenhagen, she made a passionate case for allowing vulnerable patients access to the treatment and recalled some of the patients she has met along the way.

Danish police have started cracking down on a particular crowd of impaired drivers—those who are a little too drunk or high to be riding a scooter, writes Calvin Hughes.

Since recreational cannabis was legalized in Canada in October 2018, most investors looking to catch a ride on the green wave, bumpy as it may be, have focussed on the opportunities available at home and in the United States. But while Canada may have taken the biggest leap into the legal realm, it is not the only country in which attitudes toward cannabis are changing. Here’s a look at five internationally focussed stocks that investors can look to for exposure to the emerging global cannabis industry.

Although regulatory reform has occurred across Europe, many patients still experience barriers regarding accessing medical cannabis, here Prohibition Partners explores further.

Prohibition Partners explains how legislation intended to improve availability of accessing medical cannabis for patients is being hindered by a lack of education in clinicians and regulators.